Recently, Boston Scientific (NYSE:BSX) received a notice from the Food and Drug Administration (FDA), whereby all the issues cited in the Company’s 2006 corporate warning letter have been resolved.  The warning letters from the FDA dates back to January 2006, when Boston Scientific was notified of the serious regulatory problems and corrective actions at three of ...